Abstract
Cellular therapy in renal cell carcinoma has to be included in a strategy based on the known sensitivity to immunotherapy of renal cell carcinoma. Cellular therapy was previously initiated with Lymphokine Activated Killer cells (LAK) then Tumor Infiltrating Lymphocytes (TIL). Yet, major clinical evaluations are performed on dendritic cells and allogeneic blood stem cell transplantation.
John Libbey Eurotext 2003
MeSH terms
-
Antigen-Presenting Cells / immunology
-
Carcinoma, Renal Cell / immunology
-
Carcinoma, Renal Cell / therapy*
-
Humans
-
Immunity, Cellular
-
Immunotherapy / methods
-
Kidney Neoplasms / immunology
-
Kidney Neoplasms / therapy*
-
Killer Cells, Lymphokine-Activated / immunology
-
Killer Cells, Lymphokine-Activated / transplantation*
-
Lymphocytes, Tumor-Infiltrating / immunology
-
Lymphocytes, Tumor-Infiltrating / transplantation*
-
Macrophage Activation
-
Macrophages / immunology
-
Macrophages / transplantation*